This phenomenon of progression event being largely driven by new mets has not been reported for docetaxel monotherapy. I can see it's confusing if the bolded text is omitted. Question for you, did SNTA qualify "largely driven"? Did new mets constitute 30%, 50% or 70% of PFS events?
Market Data 
Markets 
AI
